Bioequivalence of Two Tablet Forms of MK0974 (0974-045)

Phase 1CompletedNCT00965887

Merck Sharp & Dohme LLC36 enrolled

Overview

This study will evaluate the bioequivalence of two solid dose formulations of MK0974.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Migraine

Interventions

MK0974 Ethanolate formulationDRUG

Single dose MK0974 280 mg tablet in one of two treatment periods

Comparator: MK0974 Hydrate formulationDRUG

Single dose MK0974 280 mg tablet in one of two treatment periods

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Subject is in good health * Subject is a non-smoker * Subject is willing to comply with the study restrictions Exclusion Criteria: * Subject has a history of stroke, chronic seizures, or major neurological disorder * Subject has a history of cancer * Subject is a nursing mother * Subject has or has a history of any disease or condition that might make participation in the study unsafe or that might confound the results of the study

Outcomes

Primary Outcomes

Area under the curve (AUC(0 to infinity) following single dose administration of MK0974 ethanolate or hydrate formulations

Time frame: Through 48 hours postdose

Peak plasma concentration (Cmax) following single dose administration of MK0974 ethanolate or hydrate formulations

Time frame: Through 48 Hours Post Dose

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.